RT Journal Article
SR Electronic
T1 Screening for avoidant restrictive food intake disorder (ARFID) in primary care: clinical presentation and validation of the ARFID-Brief Screener in Swedish preschoolers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.26.24314270
DO 10.1101/2024.09.26.24314270
A1 Dinkler, Lisa
A1 Brimo, Katarzyna
A1 Holmang, Helena
A1 Yasumitsu-Lovell, Kahoko
A1 Kuja-Halkola, Ralf
A1 Kantzer, Anne-Katrin
A1 Omanovic, Zerina
A1 Suganuma, Narufumi
A1 Eitoku, Masamitsu
A1 Fujieda, Mikiya
A1 Fernell, Elisabeth
A1 Mollborg, Per
A1 Bryant-Waugh, Rachel
A1 Gillberg, Christopher
A1 Rastam, Maria
YR 2024
UL http://medrxiv.org/content/early/2024/09/28/2024.09.26.24314270.abstract
AB Objective: Little is known about the prevalence and clinical presentation of avoidant restrictive food intake disorder (ARFID) in preschool children, and well-validated, parent-reported screening tools are lacking. This study evaluated the diagnostic validity of the parent-reported ARFID-Brief Screener in preschool children and examined prevalence and clinical characteristics of ARFID. Method: Parents of 645 children (50.5% male, mean age 3.2 years) completed the ARFID-Brief Screener in connection with the 2.5- and 4-year routine check-ups at 21 child health services centers in West Sweden. Parents of all screen-positive and of randomly selected screen-negative children were invited to a clinical follow-up interview via phone. Co-occurring neurodevelopmental problems were assessed via questionnaire, clinical examination, and health care records. Results: Of 42 (6.5%) children screening positive for ARFID, 29 were followed up via interview, and ARFID diagnosis was confirmed in 21 (positive predicted value 72%; other diagnostic metrics: negative predictive value 94%, sensitivity 91%, specificity 79%, and overall accuracy 84%. The adjusted prevalence of ARFID was 5.9%. All children with ARFID presented with both sensory-based avoidance and low interest, and the majority (65.2%) met criteria solely through DSM-5 criterion A4 (marked interference with psychosocial functioning). The ARFID group had significantly more co-occurring neurodevelopmental problems. Discussion: ARFID is not rare among preschoolers, although prevalence might have been slightly overestimated here. The ARFID-Brief Screener showed high diagnostic validity, but follow-up assessments are necessary to confirm diagnoses and reduce false positives. Co-occurring neurodevelopmental problems were common in ARFID and may serve as early markers of increased ARFID risk.Competing Interest StatementLD: reports speaker fees from Baxter Medical AB and Fresenius Kabi AB. Other authors have no conflict to declare.Funding StatementSwedish Research Council (Vetenskapsradet; Rastam, 2018-02544; Gillberg, 538-2013-8864); Swedish Brain Foundation (Hjarnfonden) with support from Ulf Lundahls Minnesfond, Susanne Hobohms Stiftelse, and Team Rynkeby (Rastam, FO2020-0140, FO2022-0094); Japan Society for the Promotion of Science KAKENHI (Fujieda, JP18KK0263); Professor Bror Gadelius Memorial Foundation (Dinkler, 2019, 2020); AnnMari and Per Ahlqvist Foundation (Gillberg, 2018). The funding bodies were not involved in the design of the study; collection, analysis, interpretation of the data; or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Swedish Ethical Review Authority gave ethical approval for this work(Dnr 2020-01284, 2020-03908, 2021-01849).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors